The Effect of Reduced Dose of Enoxaparin on the Outcomes of Treatment With Enoxaparin

NCT ID: NCT00354796

Last Updated: 2011-07-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-07-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We hypothesize that reduced dose of enoxaparin in elderly patients will result in reduced proportion of patients with therapeutic anti Xa activity and reduced clinical efficacy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients treated with enoxaparin will be followed, sociodemographic , clinical and laboratory data will be collected. Clinical efficacy as well as adverse events will be monitored.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndrome Venous Thromboembolism Atrial Fibrillation Hypercoagulability

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* treatment with enoxaparin

Exclusion Criteria

* no
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hadassah Medical Organization

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hadassah University Hospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mordechai Muszkat, MD

Role: PRINCIPAL_INVESTIGATOR

Hadassah University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hadassah Medical Organization

Jerusalem, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mordechai Muszkat, MD

Role: CONTACT

00-972-2-6776449

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Arik Tzukert, DMD

Role: primary

00 972 2 6776095

hadas Lemberg, PhD

Role: backup

00 972 2 6777572

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

enoxap-HMO-CTIL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.